Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Meridian Auto-Injector | 252.6 | 218.4 | 183.9 | 164.8 | 129.3 | | | |
| Royalties and other | 51.8 | 83.1 | 95.2 | | | | | |
| Branded pharmaceuticals | | | | | 1,542.1 | 1,076.5 | 1,272.4 | 992.5 |
| Other | 1,472.1 | 1,263.5 | 1,857.8 | 1,823.7 | 101.5 | 227.8 | 220.4 | 95.5 |
| Total revenues | 1,776.5 | 1,565.1 | 2,136.9 | 1,988.5 | 1,772.9 | 1,304.4 | 1,492.8 | 1,088.0 |
| Revenue growth [+] | 13.5% | -26.8% | 7.5% | 12.2% | 35.9% | -12.6% | 37.2% | 24.7% |
| Meridian Auto-Injector | 15.6% | 18.8% | 11.6% | 27.5% | | | | |
| Royalties and other | -37.7% | -12.7% | | | | | | |
| Branded pharmaceuticals | | | | | 43.3% | -15.4% | 28.2% | 25.0% |
| Cost of goods sold | 616.0 | 991.9 | 601.8 | 529.8 | 510.0 | 359.7 | 567.8 | 309.2 |
| Gross profit | 1,160.5 | 573.1 | 1,535.0 | 1,458.7 | 1,262.9 | 944.7 | 925.0 | 778.9 |
| Gross margin | 65.3% | 36.6% | 71.8% | 73.4% | 71.2% | 72.4% | 62.0% | 71.6% |
| Selling, general and administrative | 548.6 | 447.4 | 691.0 | 714.0 | 636.5 | 595.4 | 490.6 | 357.4 |
| Research and development | 98.7 | 145.2 | 149.4 | 143.6 | 74.0 | 67.9 | 44.1 | 28.2 |
| Other operating expenses | 214.5 | 151.5 | 174.3 | | | | | |
| EBITDA [+] | 513.3 | -19.5 | 694.6 | 601.1 | 554.0 | 290.8 | 402.3 | 393.3 |
| EBITDA growth | -2737.9% | -102.8% | 15.5% | 8.5% | 90.5% | -27.7% | 2.3% | -5.1% |
| EBITDA margin | 28.9% | -1.2% | 32.5% | 30.2% | 31.3% | 22.3% | 27.0% | 36.1% |
| Depreciation and amortization | 214.5 | 151.5 | 174.3 | 147.5 | 147.0 | 162.1 | 113.7 | 51.4 |
| EBIT [+] | 298.8 | -170.9 | 520.2 | 453.6 | 407.0 | 128.7 | 288.6 | 341.9 |
| EBIT growth | -274.8% | -132.9% | 14.7% | 11.4% | 216.3% | -55.4% | -15.6% | -6.7% |
| EBIT margin | 16.8% | -10.9% | 24.3% | 22.8% | 23.0% | 9.9% | 19.3% | 31.4% |
| Non-recurring items [+] | 62.4 | 49.5 | 293.2 | 51.0 | 226.9 | 169.9 | 136.6 | 66.8 |
| Asset impairment | 4.5 | 41.0 | 223.0 | 47.8 | 221.1 | 149.6 | 124.6 | 66.8 |
| Interest expense, net [+] | 82.3 | -15.3 | -22.7 | -22.3 | -6.2 | 6.6 | 6.5 | -10.0 |
| Interest expense | 88.2 | 21.6 | 19.8 | 9.9 | 11.9 | 12.6 | 13.4 | 12.4 |
| Interest income | 5.9 | 37.0 | 42.5 | 32.2 | 18.2 | 6.0 | 6.8 | 22.4 |
| Other income (expense), net | -3.5 | -11.1 | -11.4 | -0.5 | -8.2 | -10.2 | 17.9 | -36.5 |
| Pre-tax income | 150.6 | -216.2 | 238.4 | 424.3 | 178.1 | -58.0 | 163.3 | 248.5 |
| Income taxes | 58.6 | 125.9 | 62.9 | 135.7 | 61.5 | -7.4 | 65.9 | 78.0 |
| Tax rate | 38.9% | | 26.4% | 32.0% | 34.5% | 12.8% | 40.3% | 31.4% |
| Earnings from continuing ops | 92.0 | -342.0 | 175.5 | 288.6 | 116.6 | -50.6 | 97.4 | 170.5 |
| Earnings from discontinued ops | | | -0.2 | 0.4 | 1.2 | -63.1 | -3.3 | 7.0 |
| Net income | 92.0 | -342.0 | 175.2 | 288.9 | 117.8 | -160.3 | 92.0 | 182.4 |
| Net margin | 5.2% | -21.9% | 8.2% | 14.5% | 6.6% | -12.3% | 6.2% | 16.8% |
| |
| Basic EPS [+] | $0.38 | ($1.40) | $0.72 | $242,505.88 | $0.48 | ($0.21) | $0.40 | $0.70 |
| Growth | -127.1% | -294.2% | -100.0% | 50001379.7% | -332.7% | -151.8% | -42.6% | -25.4% |
| Diluted EPS [+] | $0.37 | ($1.40) | $0.72 | $242,505.88 | $0.48 | ($0.21) | $0.40 | $0.69 |
| Growth | -126.4% | -294.2% | -100.0% | 50001379.7% | -332.7% | -151.8% | -41.8% | -25.6% |
| |
| Shares outstanding (basic) [+] | 242.0 | 244.3 | 243.4 | 0.0 | 240.5 | 242.9 | 242.0 | 243.2 |
| Growth | -1.0% | 0.4% | 20451814.1% | -100.0% | -1.0% | 0.4% | -0.5% | 4.9% |
| Shares outstanding (diluted) [+] | 248.5 | 244.3 | 243.4 | 0.0 | 240.5 | 242.9 | 242.0 | 246.5 |
| Growth | 1.7% | 0.4% | 20451814.1% | -100.0% | -1.0% | 0.4% | -1.8% | 5.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|